

#### Publishable Summary

The present deliverable aims at updating the degree of fulfilment of the project's objectives following the implementation of the IMI reviewers' recommended actions following the project interim review, undertaken in December 2018, via an amendment to the AMYPAD Grant Agreement, approved in December 2019.

The present report includes data about the progress made in WP3 Diagnostic and Patient Management study and WP4 Prognostic and Natural History, focusing on project performance indicators such as the number of participants and the number of scans performed to date.

In addition, we also report on the impact of COVID19 for the project activities, the closure of the EPAD Longitudinal Cohort Study, the current project management activities conducted by the Project Management Office, the first steps taken towards sustainability planning and the collaborations with other projects and initiatives currently being explored by the consortium.

**For more information:** [info@amypad.org](mailto:info@amypad.org)

**Acknowledgement:** This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

